Paul Hastings Wins Top Honors at 2019 Managing IP Americas Awards
New York, NY, and Washington, D.C. – Paul Hastings LLP, a leading global law firm, announced today that the firm received two awards at Managing Intellectual Property’s Americas Awards, which honored individuals and companies behind the most innovative and challenging IP work of the past year, as well as those driving the international IP market. The winners were announced in a ceremony that took place in New York on April 4, 2019.
Life Sciences IP Litigation Firm of the Year – United States
The Firm was honored as Life Sciences IP Litigation Firm of the Year. Managing IP reported on the practice’s multiple wins in cases including six walk-away consent judgments from generics infringing patents owned by Boehringer Ingelheim relating to Pradaxa, and the decision by the Patent Trial and Appeal Board (PTAB) invalidating a patent relating to AbbVie’s drug Humira.
The practice was also noted for wins on behalf of Sunovion Pharmaceuticals, after the Court of Appeals for the Federal Circuit affirmed that multiple generic versions of the billion-dollar antipsychotic drug Latuda would infringe Sunovion’s patent; and a trial win for Orexigen that a generic version of the weight loss drug, Contrave would infringe Orexigen’s patents.
The award from Managing Intellectual Property follows numerous accolades for the Life Sciences IP Litigation practice, including LMG Life Sciences’
Outstanding Litigator of the Year – PTAB
To date, Modi has handled more than 400 post grant proceedings at the PTAB since 2012. The Firm’s Patent Office Practice has also been
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.